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A CANCER-TARGETED GOLD NANOPARTICLE-BASED MRI CONTRAST 
AGENT   
 
Nagwa El-Baz 
July 5, 2018 
 
In oncology, imaging plays a major role in terms of early detection and treatment 
of most types of cancer. Magnetic resonance imaging (MRI) is mostly used for cancer 
diagnosis due to its excellent contrast resolution. However, MRI for cancer diagnosis is 
somewhat limited by its sensitivity. In this thesis, we assessed the ability of theranostic 
platform consisting of gold nanoparticles functionalized with a cancer targeting aptamer; 
AS1411 and gadolinium chelate (Dotarem thiol derivative; Gd (III)-DO3A) as a MRI 
contrast agent to target malignant tumors by enhancing the MRI contrast of the detected 
tumor. The proposed technology is a novel injectable contrast agent for detection and 
monitoring of malignancies by MRI. The gold nanoparticle core (GNPs) enhances the 
pharmacokinetic properties of the proposed contrast agent, increases its potency, and 
provides a good way to co-localize the aptamer with the contrast agent. AS1411 is anti-
nucleolin aptamer that binds to nucleolin protein, which is highly expressed in cancer cells, 
leading to selective accumulation in cancers cells. The ability of the proposed contrast 
agent to target cancer cells and enhance MRI contrast was assessed using MDA-MB-231 
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triple negative breast cells and MCF-10 human mammary epithelial cells. Moreover we 
assessed the biodistribution and toxicity of the proposed contrast agent in vivo.  
 The results presented in this thesis demonstrate the superiority of the proposed 
contrast agent with respect to the current commercial contrast agents (e.g., MultiHance). 
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CHAPTER 1. INTRODUCTION 
 
 
1.1. Current Technology for Cancer Diagnosis: 
Cancer is a major public health problem worldwide and the second leading cause 
of death in the United States [1]. Cancer is a group of diseases that can be characterized by 
uncontrolled growth of abnormal cells. If the cell growth is not controlled, it can result in 
metastasis of the cancer, and eventually, death. In 2018, about 1.7 million new cancer cases 
are expected to be diagnosed [2]. Moreover, about 609,640 Americans are expected to die 
of cancer in 2018 (see Figure 1) [2]. As reported by the American Cancer Society, in 2015, 
the cancer mortality rate had dropped 26% from its peak in 1991. This decline translated 
into about 2.4 million deaths avoided during this time period [2]. One of the main reasons 
for this drop is the improvement in early detection and treatment of most types of cancer. 
Nowadays, medical imaging plays an important role in diagnosis, staging, monitoring 
therapeutic response, and treatment planning for almost all cancer types. Each year in USA, 
more than 71 million Computed Tomography (CT) and 33 million Magnetic Resonance 
Imaging (MRI) scans are performed for the purpose of detection of primary or metastatic 
malignant tumors [3]. CT, MRI, and Positron Emission Tomography (PET) are the three 
major imaging modalities in clinical radiology that are used in cancer diagnosis and 
treatment.   
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CT scans combine a series of X-ray images which are taken from different angles 
and uses computer processing to create cross-sectional images of the interested body organ. 
CT is the most commonly used modality because it is fast and has widespread availability. 
CT images provide high resolution of the organ of interest, which can be used to extract all 
the anatomical features of any detected tumors. Unfortunately, the sensitivity and 
specificity of diagnosing malignant tumors based only on the anatomical features are low, 
which makes it unacceptable in the clinical setting. Moreover, some CT intravenous 
contrast agents are contraindicated with some patients with renal problems. Finally, CT has 
a limited ability in detected the tumors that may exist in the soft tissues (e.g., brain, liver, 
etc.) 
 
Figure 1: Estimated Numbers of Cancer Cases for 2018 in the USA, excluding basal 




MRI, also known as nuclear magnetic resonance imaging, is a scanning technique 
for creating three dimensional detailed images of the regions of interest. To perform an 
MRI scan, the person is positioned within an MRI scanner that forms a strong magnetic 
field (that forces the magnetic moment of protons in the body tissues to be aligned with the 
magnetic field). Then, a radiofrequency pulse is applied which disrupts the protons and 
forces them to rotate 90 or 180 degrees against the pull of magnetic field. When the 
radiofrequency pulse is turned off the protons rotate to realign again with the magnetic 
field, releasing electromagnetic energy. MRI scanners detect the released electromagnetic 
energy as well the time taken for protons to relax or realign with the magnetic field. These 
two factors are different depending on the environment of the protons. Technicians can 
differentiate between different body tissues based on these factors. T1-weighted (spin-
lattice) and T2-weighted (spin-spin) are the basic two MRI image types. A T1-weighted 
image is useful for assessing the cerebral cortex, identifying fatty tissue, characterizing 
focal liver lesions and in general for obtaining morphological and anatomical information, 
as well as for post-contrast imaging. A T2-weighted image is useful for detecting edema 
and inflammation, revealing white matter lesions and assessing zonal anatomy in the 
prostate and uterus. The main advantage of MRI scans is its ability to detect tumors/lesions 
in the soft tissues at an early stage [4]. However, MRI sensitivity and specificity for 
diagnosing malignant tumors is low. 
PET is a nuclear medicine functional imaging technique that is used to observe 
metabolic processes in the body. PET is both a clinical and research tool. PET relies on 
cancer-selective uptake of radiolabeled sugars and provides better information for 
malignant status for some (but not all) tumor types; however, its use is limited by its 
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expense and the necessity for short-lived radiopharmaceuticals that require a synchrotron 
source. Also, its sensitivity and resolution for diagnosing tumors is low compared with CT 
and MRI. On the other hand, the main advantage of PET is it has high specificity of tumor 
diagnosis.  
 
1.2. Current Imaging Contrast Agents: 
In most cases before applying MRI and CT scans intravenous contrast agents are 
administered. Contrast agents are chemical materials that improve visualization of tissues 
and body organs. For CT, all contrast agents are iodine-based reagents that absorb and 
diffract X-rays. There are 13 different CT contrast agents that are FDA-approved. There 
have been no novel CT contrast agents approved since 1997 [5]. Iodine contrast agents 
have mild and self-limiting adverse effects in healthy individuals but individuals with 
impaired renal function can have severe and serious adverse effects including anaphylaxis 
and nephropathy. Moreover iodine-based contrast agents have short half-lives and rapid 
clearance, and therefore may require multiple injections [6]. 
For MRI, most common contrast agents are gadolinium-based (11 types are FDA-
approved). Gadolinium ions are paramagnetic and shorten the relaxation time of the excited 
protons in body tissues and enhance changes in signals between adjacent tissues, which 
may depend on tissue type or blood flow. Like CT contrast agents, MRI contrast agents are 
generally safe for all patients except patients with impaired renal function. These contrast 
agents may develop nephrogenic systemic fibrosis (7). 
The existing contrast agents for CT and MRI are effective at enhancing anatomical 
imaging, but they are not cancer-specific and largely fail to distinguish malignant from 
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benign lesions. That is why there is an urgent need to develop cancer-targeted contrast 
agents to diagnose cancer at an early stage. The Molecular Imaging and Contrast Agent 
Database (MICAD) lists more than 5,000 targeting compounds that have been reported in 
the literature with around 2,000 for cancer diagnosis. Many cancer-targeted ligands have 
been tested, such as peptides, antibodies, small molecules, and aptamers. Aptamers have 
numerous advantages due to ease of synthesis, their nano-size, physical properties, and 
versatile chemistry. 
 
1.3. Anti-Nucleolin Aptamer AS1411: 
AS1411 is a quartet G-rich oligodeoxynucleotide that specifically binds to a 
phosphoprotein called nucleolin that is overexpressed in almost all cancer cells where it is 
found on the cell surface and in the cytoplasm. Nucleolin is absent from the cell surface 
and cytoplasm of almost all normal cells. AS1411 has apoptotic induction activity through 
binding to nucleolin, which inhibits nucleolin binding to BCL2 mRNA (BCL2 is a family 
of regulatory proteins that regulate cell apoptosis by either inducing or inhibiting 
apoptosis). AS1411 is taken up in cancer cells by macropinocytosis, which leads to specific 
accumulation in cancer cells. The majority of targeted agents in MICAD database are 
peptides or antibodies, which target specific molecular targets that are expressed in small 
subset of cancers, whereas AS1411 has a near-universal cancer targeting mechanism 
because nucleolin is expressed in most cancer types. AS1411 is the first aptamer to be 
tested in human trials, and it passed phase I and II clinical trials. More than 100 patients 
were treated with no serious adverse events reported. Moreover, there is some evidence of 
clinical benefit. However, the response was low due to poor pharmacokinetics (rapid 
6 
 
clearance from the body and serum concentration is not enough to kill most cancer cells) 
and low potency of AS1411. 
 
1.4. Conjugation of AS1411 with Gold Nanoparticles (GNPs): 
  Gold nanoparticles (GNPs) are extensively employed as therapeutic and diagnostic 
platforms in biotechnology-based applications. GNPs have unique dimensions, tunable 
functionalities on the surface and display controllable drug release. While traditionally, 
GNPs have been functionalized with therapeutic agents, disease targeting agents or 
diagnostic/ contrast agents, recent efforts have focused on combining disease targeting, 
diagnostic technologies and therapeutics into a single theranostic agent.  
            In this thesis, we propose a theranostic construct using GNPs conjugated with 
AS1411 (cancer targeting therapeutic aptamer) and gadolinium chelate (Dotarem thiol 
derivative; Gd (III)-DO3A) as MRI contrast agents [10] (see Figure 2). Conjugation of 
AS1411 with GNPs has many advantages over using AS1411 alone. AS1411-GNPs have 
a dramatic increase in uptake by cancer cells (along with up to 50-fold increase in potency 
against cancer cells) while maintaining cancer selectivity (no effect on normal cells) and 
display antitumor activity in mice with no evidence of toxicity [9]. Additionally, AS1411 




Figure 2: GNP functionalized with Gd (lll) DO3A-SH and AS1411. 
 
Gd (III) ions cannot be administered directly in their ionic form because they are 
very toxic. Gd (III) ions interfere with calcium channel and protein binding sites, and also 
accumulate in liver, bones, spleen, and kidney. That is why Gd(III) ions are formulated 
with chelating agents to prevent tissue interaction and minimize their toxic effect [11] (see 
Figure 3). Here we use DO3A (1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic 




Figure 3: Gd ion is chelating to DO3A with thiol group. 
                                            
The first goal of this study is to investigate the ability of the proposed contrast agent 
to enhance the contrast of MRI images using MDA-MB-231 triple negative breast cells 
line and MCF-10 human mammary epithelial cells line. The second goal is to evaluate the 
















                              
 
CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1. Chemicals and Materials: 
HAuCl4·3H2O was purchased from Alfa Aesar (Tewksbury, MA). Citric acid, 
trisodium salt (Na3C6H5O7), Sodium Borohydride (NaBH4), Gadolinium trichloride 
hexahydrate (GdCl3·6H2O), dithiothreitol (DTT) and anhydrous sodium bicarbonate 
(NaHCO3) were purchased from Sigma Aldrich (St. Louis, MO). 10X PBS (pH 7.4) and 
OliGreen dye were purchased from Thermo Fisher Scientific (Waltham, MA). Nanopure 
ultrapure water (Barnstead, resistivity of 18.2 MΩ-cm) was used for preparing all aqueous 
solutions. Analytical grade hydrochloric acid (HCl) and nitric acid (HNO3) were purchased 
from VWR (Rednor,PA). Aqua Regia solution (3 parts HCl and 1 part HNO3) was used to 
clean all glassware for GNP synthesis. The tetraazamacrocycle 10-(2-sulfanylethyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (H4DO3ASH) was purchased from 
Macrocyclics, Inc. (Dallas, TX). Oligonucleotides having a regular DNA backbone 
(phosphodiester), a 5’-Thiol C6 S-S modification (Thio-MC6-D), 5’-6T spacer (for 
AS1411 and CRO) and high pressure liquid chromatography (HPLC) purification were 
supplied by Integrated DNA Technologies (IDT) [Coralville, IA].  





 and TTTTTT (CTR).  
MDA-MB-231 breast cancer cells and MCF-10A healthy mammary gland cells were 
purchased from ATCC (Manassas, VA). MEBM media with Bullet Kit Media were 
purchased from Lonza Group (Basel, Switzerland). DMEM, Fetal Bovine Serum (FBS), 
10X Trypsin, Penicillin/Streptomycin (Pen/Strep) & Gentamicin were all purchased from 
Thermo Fisher Scientific (Waltham, MA). Phosphate-buffered saline (PBS) 1X without 
calcium or magnesium was purchased from Gibco. Accutase solution was purchased from 
Sigma-Aldrich.  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), MTT 
reagent was purchased from Sigma (Cream Ridge, NJ). Sodium dodecyl sulfate (SDS) was 
purchased from Thermo Fisher Scientific. Tissue culture flasks, dishes and plates were 
purchased from Thermo Fisher Scientific. Amicon Ultra 15.0 ml centrifugal filters with 
Ultracel-30 (30000 MWCO) were purchased from Merck Millipore (Billerica, MA) to 
remove excess oligonucleotide and Gd(III)-DO3A-SH. The 0.6 ml Eppendorf 
microcentrifuge tubes were purchased from Sigma Aldrich (St. Louis, MO) to mount 
samples at 9.4 T (Agilent) MRI scanner.  
UV absorption spectra were measured with a UV Visible Spectrometer (Varian 
Cary 50 BIO UV, Agilent Technologies, Santa Clara, CA). Dynamic Light Scattering 
measurements (DLS) were acquired on a Zetasizer (Zetasizer Nano ZS90, Malvern 
Instruments Ltd., Westborough, MA). The Zeta potential measurements were acquired 
using a NanoBrook Zeta PALS Zeta Potential Analyzer (Brookhaven Instruments, 
Holtsville, NY). Tunneling electron microscopy (TEM) studies was performed on the FEI 
Tecnai F20 TEM to determine GNP morphology and distribution. Fluorescence studies 
were performed on the enhanced darkfield Cytoviva fluorescence microscope (CytoViva, 
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Inc., Auburn, AL). 
2.2. Chemical synthesis of 4 nm GNPs: 
Gold nanoparticles were synthesized according to the procedure described by 
Murphy and coworkers [12]. A 2.5 mL of 0.01M citric acid, trisodium salt was added to 
95.0 mL of nanopure water under intense stirring. Then, 2.5 mL of 0.01M HAuCl4 solution 
was added followed immediately by 3.0 mL of 4ºC 0.1M sodium borohydride. The solution 
was stirred for 2 hours. GNPs size was determined by UV/vis and dynamic light scattering.  
 
2.3. Chemical Synthesis of Gadolinium (III) DO3A-SH:  
The tetraazamacrocycle 10-(2-sulfanylethyl)-1,4,7,10-tetraaza cyclododecane-
1,4,7-triacetic acid (DO3ASH) was chelated with GdCl3 by mixing an aqueous solution of 
DO3A-SH (15.8 µmol, 100 μl) with an aqueous solution of GdCl3 (347 mM, 50 µL) at 
room temperature [13-15] The reaction mixture pH was then adjusted to 6.0 with 1.0 M 
sodium bicarbonate and the mixture incubated overnight at 60ºC. During the reaction, the 
pH was monitored three times and bicarbonate solution added as necessary to keep the pH 
in the range of 6-7. Afterwards, the reaction mixture pH was adjusted to 9-10 using sodium 
bicarbonate and then centrifuged at 3000 g for 15 minutes. The sample was then vacuum 
filtered and the precipitate air-dried.  
 
2.4. Preparation of AS1411/CRO/CTR for conjugation to GNP: 
Oligonucleotides having a regular DNA backbone (phosphodiester), a 5’-Thiol C6 
S-S modification (Thio-MC6-D), and high pressure liquid chromatography (HPLC) 
purified were supplied by Integrated DNA Technologies (IDT). Oligonucleotide solutions 
were prepared as previously reported [16]. Briefly, 500 µl of 500 µM oligonucleotide 
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solution was prepared by suspending AS1411/CRO/CTR in nanopure water. Prior to use, 
the disulfide protecting group on the oligonucleotide solution was cleaved with 
dithiothreitol (DTT). A 250 µl solution of 1M DTT was added to 60 µl of 500 µM 
oligonucleotide solution and heated at 90°C for 1 hour (0.1 M DTT, 0.18 M phosphate 
buffer (PB), pH 8.0). The cleaved oligonucleotides were purified using a NAP-5 column 
eluted with PB. Thereafter, the eluted solution of freshly cleaved oligonucleotides was 
added to gold nanoparticle dispersions. 
 
2.5. Chemical synthesis of GNP–Gd(III)-DO3A-SH- Oligonucleotide:  
Gold nanoparticles (GNP) were functionalized with the MRI contrast agent Gd(III)-
DO3A-SH and/or thiol-deprotected oligonucleotide (AS1411/CRO/CTR). The freshly 
cleaved oligonucleotide solution was added to the GNP dispersion (~170 nM) [12] to bring 
the mixture to 1.2 µM oligonucleotide concentration [16] while simultaneously adding 
Gd(III)-DO3A-SH to achieve 1.3 mM contrast agent concentration. The GNP-
Gd(III)DO3A-SH-Oligonucleotide solution was incubated at room temperature for 20 
minutes and then sonicated for 10 minutes. The solution was incubated overnight at 37ºC. 
The concentration of NaCl was gradually increased to 137 mM using 10X PBS over 3 days. 
During each salt addition, the GNP-Gd(III)-DO3A-SH-Oligonucleotide solution was 
sonicated for 60s followed by incubation at 37ºC. As mentioned, the excess oligonucleotide 
and Gd(III)-DO3A-SH were removed via centrifugal filtration at 3000g for 30 min. The 
concentrated solution was re-suspended to 15.0 ml with 1.0 X PBS and filtered two more 
times before use.  
2.6. Oligonucleotides Quantification:  
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45.0 μl of the centrifuged pellets of GNP-Gd(III)DO3A-SH-Oligonucleotide were 
redispersed to 2.0 ml samples at 45X dilution in GNP stripping solution (5 μL of 1.0 M 
DTT, 0.1M phosphate buffer (pH 8)) and incubated overnight at 37 °C to cleave the gold 
oligonucleotide-thiol bond. Within 24 hours, after the gold nanoparticles precipitate, the 
supernatant was collected and the released oligonucleotides were quantified using UV 
absorption spectra. 
 
2.7. Transmission Electron Microscopy: 
Transmission electron microscopy (TEM) images were obtained using a FEI Tecnai 
F20 TEM. A field emission gun (FEG) was used for the electron source and the studies 
were performed with an accelerating voltage of 360 keV. The samples were prepared by 
suspending 20.0 μl of 0.5-0.6 μM concentration of GNP samples onto a C-flat holey carbon 
film mesh on copper grids and air dried overnight. The size histogram analysis of the TEM 
images was performed with ImageJ software.  
 
2.8. Fluorescence:  
The samples (the synthesized GNPS) were tagged with the fluorescent dye 
OliGreen™ using the protocol provided by the manufacturer. Excess dye was removed 
through centrifugation at 3000 rpm for 30 min. A Modulus Fluorimeter (Promega, 
Madison, WI) was used to measure the fluorescence of the samples (Blue module: Ex 460 
nm, Em: 518-570 nm). The samples were also imaged with an enhanced darkfield 
(Cytoviva) fluorescence microscope. The samples were prepared by drop casting 10.0 μL 
of sample onto a glass microscope slide (Fisherbrand Superfrost Plus) and then placing a 
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coverslip overtop (VWR micro cover glass). Lacquer (Nail Polish) was then used to create 
a waterproof seal around the edges. The samples were imaged at 60x magnification. 
 
2.9. Gadolinium quantification with Energy Dispersive X-Ray Analysis:  
Energy Dispersive X-ray Analysis (EDAX) was performed on a Zeiss SUPRA 35 
FE-SEM (Zeiss Peabody, MA) at 20 KeV incident beam at 8.1 mm working distance. The 
atomic ratios of Gd:Au were measured for GNP –Gd(III)-DO3A-SH- oligonucleotide to 
quantify Gd content per GNP.  
 
2.10. Cell Culture development: 
MDA-MB-231 and MCF-10A cells were maintain DMEM and MEBM, 
respectively. Cells were cultured in a 5% CO2 incubator at 37°C and media were replaced 
with fresh media every two to three days. Cells were subcultured every four to five days 
using PBS for MDA-MB-231 and accutase for MCF-10A. 
 
2.11. MRI Agarose Phantoms:  
Samples for MRI imaging were prepared by mixing different concentrations (1200, 
300 and 75 nM) of gold nanoparticles functionalized with Gd(III)- DO3A-SH and 
oligonucleotide (AS1411/CRO/CTR) with agarose solution (0.7%, 55°C) in 1:1 ratio in 0.5 
mL Eppendorf microcentrifuge tubes. The uniform dispersions were allowed to stand at 
room temperature for 30 minutes to solidify. Samples were mounted on a mesh grid and 
MRI images were acquired on the 9.4 T instrument (Agilent) for T1 W and T1 MRI 
measurements. Concentrations of gold nanoparticles (1200 nM, 300 nM and 75 nM) 
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functionalized with Gd(III)- DO3A-SH and oligonucleotide (AS1411/CRO/CTR) were 
diluted in agarose solution (0.7%) and mounted on the 9.4 T instrument holder for their T1 
W and T1 MRI measurements. 
 
2.12. MR imaging: 
All MR imaging data were acquired using Agilent 9.4 T horizontal bore MRI 
system equipped with Agilent 205/120 HD gradient coil (Agilent Technologies, Santa 
Clara, CA, USA). A RAPID 72-mm volume coil was used for signal transmission and 
detection (RAPID MR International, Columbus, OH, USA). After a quick 3-plane gradient 
echo-based scout scan to verify sample positioning, T1-Weighted images were obtained 
using a standard spin echo multi-slice (SEMS) imaging sequence with the following 
parameters: TR/TE = 500/10 msec; matrix size = 128 x 128; field of view (FOV) = 40 x 
40 mm2; 13 slices with a slice thickness of 1.0 mm. When acquiring data for T1 calculation 
purposes, a fast spin echo multi-slice (fSEMS) sequence was used with the following 
parameters: TR (array) = 6000, 4700, 3600, 2800, 2200, 1700, 1300, 1000, 800 msec; 
effective TE = 20 msec; matrix size = 128 x 128; field of view (FOV) = 40 x 40 mm2; 9 
slices with a slice thickness of 2.0 mm and 2 averages. All data from 9.4T MRI system 
were converted to DICOM format using VNMRJ 4.0 interface before transferring to other 
software for further data processing. Samples were also scanned using a 3 T Siemens 
MAGNETOM Skyra (Siemens Medical Solutions, Malvern, PA, USA) with a 20 channel 
head coil. A turbo spin echo (TSE) sequence was used under 3 T for T1 quantification: TR 
(array) = 5000, 2000, 1000, 750, 500 msec; TE = 10 msec; matrix size = 256 x 256; field 




2.13. Determination of GNP –Gd(III)-DO3A-SH- Oligonucleotide cellular uptake using 
live MDA-MB-231 and MCF-10A: 
 
MDA-MB-231and MCF-10A were treated with different concentrations of gold 
nanoparticles (1200 nM, 300 nM, and 75 nM) functionalized with Gd(III)-DO3A-SH and 
AS1411/CRO/CTR made in complete DMEM and MEBM, respectively, and incubated for 
24, 48, 72 & 96 hour time points at 37°C to allow cell uptake and localization. After the 
prescribed incubation time, the media was discarded and cells were washed 3 times with 
1X PBS to remove any excess and unbound gold nanoparticles that were not internalized 
within the cells. Cells were detached from the monolayer using TryPLE and accutase 
solutions for 5 minutes at 37°C, transferred to a 15 mL conical tube, and centrifuged at 700 
rpm to pellet the cells and separate any remaining unbound gold nanoparticles. Excess gold 
nanoparticles, TryPLE, and accutase solutions were removed and cell pellets were 
suspended in 100 l of 1X PBS, and transferred to 0.5 mL tubes with the addition of 100.0 
µl of 1.4% agarose to give a final concentration of 0.7% agarose for a clear homogenous 
solution. Cells were then mounted on the 9.4 T instrument mesh grid holder for T1-
Weighted and T1 MRI measurements. 
 
2.14 T1-Weighted image analysis algorithm: 
The T1-Weighted image calculation algorithm starts with single-click selection of 
the two Eppendorf microcentrifuge tubes (0.5 ml) to be analyzed (see Fig. S5 (a)). Then a 
background removal and a 3D region-growing algorithm is applied to extract the volume 
of interest (VOI) that contains each microcentrifuge tube (0.5 ml) in the middle of the VOI 
(see Fig.S5 (b-f)). The second step is to perform a two-step 3D registration technique to 
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guarantee a voxel-on-voxel match between sample and control for accurate relaxivity 
calculations. The registration technique begins with a global alignment using a 3D affine 
transformation model. In order to perform the global registration, the distance maps inside 
the reference and target microcentrifuge tubes (0.5 ml) are generated by finding the 
minimum Euclidean distance for every inner voxel to the object boundary using a fast 
marching level set. Then a 3D affine transformation with 12 degrees of freedom is applied 
to align the target microcentrifuge tube (0.5 ml) to the reference one by maximizing the 
mutual information of the generated distance maps. The second registration step is to 
perform a non-rigid alignment (a step confirming voxel on voxel match) using a 
multiresolution elastic registration approach which is based on 3D cubic B-splines with 
four-stage multiresolution and using limited memory Broyden-Fletcher-Goldfarb-Shanno 
(L-BFGS-B) optimization [19].  
The traditional method to calculate the relaxivity is as follows: 
 
Since after aligning the MRI data, we have voxel-on-voxel match, then the proposed 
equation to calculate the relaxivity is as follows: 
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑅𝑒𝑙𝑎𝑥𝑖𝑣𝑖𝑡𝑦 (𝑅) =






× 100                              (2)      
Where N is the number of voxels in each image, Ii is the MRI signal of the test cells and gi 
is the MRI signal of control cells as demonstrated in Figure 4.  
Note that each MR scan has one microcentrifuge tube (0.5 ml) filled with water. All our 
data from any MRI scan is divided by the average signal of water. Finally, after calculating 
   𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑅𝑒𝑙𝑎𝑥𝑖𝑣𝑖𝑡𝑦 (𝑅) =  
(𝑇𝑒𝑠𝑡)𝑎𝑣𝑟−(𝐶𝑜𝑛𝑡𝑟𝑜𝑙)𝑎𝑣𝑟
(𝐶𝑜𝑛𝑡𝑟𝑜𝑙)𝑎𝑣𝑟
∗ 100                                 (1) 
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the relaxivity using Eq. 2, the proposed approach generates the color map that shows the 
relaxivity of each voxel as shown in Figure 5. 
                
(a) Test                                           (b) control             
Figure 4: Illustration of the proposed relaxivity calculation. 
 
 
 Figure 5: An illustration of color map generated of relaxivity 
enhancement.  Red color means 100% improvement in the relaxivity as demonstrated in 
the color coded bar. 
 
2.15. In vivo Biodistribution and Toxicity study: 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Louisville. Fifty healthy female Sprague Dawley 
rats (4 weeks old) were purchased from Charles River Laboratories (Wilmington, MA). 
Rats were fed a standard chow diet and water for the entire duration of the experiment. At 
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6 week ages, blood samples were collected from the saphenous vein of all animals to be 
used as a baseline control. On day 2, the animals were randomly divided into 5 groups and 
injected through tail vein with GNPs coated with Gd(III)- DO3A-SH and/or thiol-
deprotected oligonucleotides (AS1411, CRO (an analog of AS1411 with all G’s replaced 
with C’s), and CTR (a short sequence of thymidylates), MultiHance (Gadobenate 
Dimeglumine Injection), or saline ( MultiHance and saline were used as controls). Rats 
were euthanized using CO2 and blood samples were collected through Cardiac Puncture 
using 23G one inch syringes after two or fourteen days from each group. Blood samples 
were centrifuged (800g) to collect 200 µl of serum for the general health profile chemistry 
panel and organs were collected and stored in 10% formalin for ICP-MS analysis.  
 
(a) Inductively Coupled Plasma Mass Spectrometry (ICP-MS): 
The sample preparation for ICP-MS/MS analysis consisted of a microwave acid 
digestion of the collected tissue. The samples (about 80-200mg) were placed into 10 ml 
Pyrex digestion vials, 2 ml of concentrated trace metal grade nitric acid was added, and 
samples were kept at room temperature for 2 hours as pre-digestion step. Then 0.5 ml of 
1:1 hydrochloric acid and 20 ml of internal standard solution containing Indium was added 
and the closed vials were microwaved in a CEM Discovery digestion system. The 
temperature program consisted on a 10 minute ramp to 110 °C with one minute holding 
followed by a 10 minute ramp to 195 °C with a 15 minutes holding time. The maximum 
pressure was set at 295 PSI and the maximum power of 300 Watts. 
Once the digestion was completed the samples were brought to a final volume of 
20 ml with doubly deionized water for a final concentration of 10 ppb of the internal 
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standard before the analysis. 
The total element analysis was carried out using an Agilent ICP-MS/MS system. It 
consisted on a SPS 4 Autosampler, a micromist quartz nebulizer, a Double pass Scott spray 
chamber cooled to 2°C, a 2.5 mm ID standard torch, nickel sampler and skimmer cones. 
The quantification was performed by the external calibration method with gold and 
gadolinium standards in the 0.5 to 200 ppb range with Indium used as internal standard at 
a concentration of 10 ppb. For the calibration, R values of 0.9990 or larger and blank 
equivalent concentration lower than 50 ppt were obtained for both elements. 
The analysis was performed for the following isotopes: 197Au, 157Gd and 155In. The 
integration time per isotope was set at 0.1 s, and the probe rinsing program consisted on a 
10% nitric acid followed by 5% HCl solutions. 
 
(b) General Health Profile Chemistry Analysis: 
Blood chemistry analysis (General Health Profile) was performed on 50 Sprague 
Dawley (Crl:SD) rats. Blood was taken before treatment exposure and after (day 2 and day 
14) after euthanasia. The GHP was performed at U of L through Research Resource Center 
(RRC) and detects the following: alkaline phosphate (ALP), alanine transaminase (ALT), 
creatinine (CREA), total bilirubin (TBIL), and blood urea nitrogen (BUN).  
For the baseline measurements (before treatment), the blood volume taken from the 
rats (6 weeks old) was 100ul for each rat through the saphenous vein. After blood 
collection, the blood was centrifuged to collect 40 µl of serum which was needed for the 
GHP analysis (minimum detection limit). After euthanasia (day 2 or 14), blood collection 
was performed through the heart’s atrium yielding around 1 ml. This allowed for a higher 
21 
 
volume of serum (200 µl) to be collected and analyzed through the GHP.  
 
2.16 Statistical Analysis: 
For blood chemistry results, we performed two statistical tests to analyze the data 
that were collected. The first test is based on using unpaired t-test by assuming all the 
involved biomarkers in this experiment are independent. The second statistical test is based 
on using ANOVA test in order to make group analysis in case the collected biomarkers are 
dependent/correlated. For both tests we calculated the p-value to determine if there is the 
significant change in the measured biomarkers that they may related to the toxic effect of 














3.1 Characterization of solutions of GNP and GNP Gd(III)DO3A-SH Oligonucleotide:  
Dynamic light scattering (DLS) was measured to determine the size distribution 
profile of the particles and hydrodynamic size in solutions of GNP and GNP Gd(III)DO3A-
SH oligonucleotide. Transmission electron microscopy (TEM) was used to determine the 
size of gold nanoparticles GNP and GNP Gd(III)DO3A-SH oligonucleotide. Zeta Potential 
were measured to determine particles stability for solutions of citrate capped GNP and 
GNP Gd(III)DO3A-SH oligonucleotide. 
 
Table 1: DLS, TEM, Zeta Potential characterization of citrate capped GNP and GNP 
Gd(III) DO3A-SH Oligonucleotide. 
Sample Hydrodynamic size (nm) TEM (nm) Zeta Potential (mV) 
GNP Gd(III) 
DO3A-SH AS1411 
13.5 ± 2.1 3.4 ±0.6 -20.9 ± 1.1 
GNP Gd(III) 
DO3A-SH CRO 
19.3 ± 2.5 3.3 ± 0.6 -57.6 ±1.0 
GNP Gd(III) 
DO3A-SH CTR 
9.83 ± 1.45 5.45 ± 1.42 -42.67 ±4.15 
GNP Citrate 4.88 ± 0.51 4.0 ± 0.7 -16.25 ± 2.30 
 
Table 1 shows that the compact monomeric quadruplex formation of AS1411 leads 
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to the relatively smaller hydrodynamic diameter of GNP-Gd(III)-DO3A-SH-AS1411 (13.5 
± 2.1) in comparison to GNP-Gd(III)-DO3A-SH-CRO (19.3 ± 2.5). A zeta (ζ) potential of 
-(58 – 20) mV was observed for GNP Gd(III)DO3A-SH Oligonucleotide solutions, which 
displayed high stability and resistance to aggregation in PBS dispersions. On the other 
hand, the citrate capped gold nanoparticles (GNP) aggregated in PBS dispersions and 
therefore zeta (ζ) potential and hydrodynamic size characterizations were performed in 
nanopure water. 
 
Figure 6: TEM image and particle size histogram for GNP-Gd-DO3A-SH-AS1411 
(n=500) 
 




Figure 8: TEM image and particle size histogram for GNP-Gd-DO3A-SH-CTR (n=500) 
Figures 6-8 show that TEM images of GNP-Gd(III)DO3A-SH-Oligonucleotide  
(AS1411/CRO/CTR) reveal average gold core diameters of (3-6) nm.  Although the 
particles are coated with aptamer and contrast agent, only the gold core of the particles is 
electron dense enough to have contrast in this imaging technique using formvar coated 
sample grids. TEM characterizations were performed in nanopure water. Citrate-capped 
GNP and GNP-Gd(III)DO3A-SH Oligonucleotide solutions were stable for more than 6 
months in solution at 4ºC and 37ºC, respectively based on UV-vis measurement. 
 
3.2. Oligonucleotides Determination and quantification: 
(a) OliGreen Fluorescence and Darkfield microscopy: 
As demonstrated in table 2, three samples solution were stained with OliGreen dye. 
GNP Gd(III) DO3A-SH,  1 X PBS Buffer, and GNP Gd(III) DO3A-SH AS1411 to 
determine the presence of oligo in the samples. The test solution (GNP Gd(III) DO3A-SH 






Table 2: OliGreen staining fluorescence values (FL) obtained for GNP Samples using 
Blue Module (Excitation 460 nm; Emission 515-570 nm). 
Samples Fluorescence (FLU) 
GNP Gd(III) DO3A-SH AS1411 3988.6 
GNP Gd(III) DO3A-SH 37.5 
1 X PBS Buffer 74.6 
 
OliGreen tagged GNP-Gd(III) DO3A-SH-AS1411, GNP-Gd(III)-DO3A-SH, and 
non-OliGreen tagged GNP-AS1411 were imaged using dark field fluorescence microscopy 
(see figure 9). The left side of the figure demonstrates gold nanoparticles images. While 
the right sides demonstrates OliGreen-tagged particles. 
 
Figure 9: Darkfield (Left) and Fluorescence (Right) characterization of OliGreen tagged 
GNP-Gd(III) DO3A-SH-AS1411(Top), GNP-Gd(III)-DO3A-SH (middle) and non-





(b) UV-visible Absorption Spectra Method: 
The concentration of oligonucleotides (max = 280 nm) and gold nanoparticles (max 
= 530 nm) were calculated using Beer’s Law equation (A= e L c; A is the absorbance, e is 
the molar extinction coefficient,(extinction coefficient values: 3620000,  323500, 268800, 
49200 L(mole.cm) for 4nm gold nanoparticles, AS1411, CRO, CTR respectively), L is the 
path of length of the cell holder, and c is the concentration)[20][21]. Then the number of 
oligonucleotides per gold nanoparticle was calculated by dividing the concentration of 
oligonucleotides by the concentration of gold nanoparticles. 
 
Table 3: Number of oligonucleotides per gold nanoparticles for two aliquots. 
Sample Quantification of Oligonucleotides 
GNP Gd(III) DO3A-SH AS1411  10 ± 2 
GNP Gd(III) DO3A-SH CRO 9 ± 2 
 
3.2 Gadolinium quantification:  
Gadolinium and gold were quantified using Energy Dispersive X-Ray Analysis 
(EDAX). The sample is bombarded with an electron beam, which leads to electron transfer. 
The transferring electrons must give up some of their energy by emitting an X-ray.  Each 
atom of every element releases a unique amount of X-ray during electron transferring 
process.  
An EDX spectrum demonstrates peaks corresponding to the energy levels for which 
the most X-rays had been received. Each of these peaks is unique to an atom, and therefore 
corresponds to a single element. The higher a peak in a spectrum, the more concentrated 





Figure 10: Energy Dispersive X-Ray Spectrum of GNP Gd(III) DO3A-SH AS1411 
 
 





Figure 12: Energy Dispersive X-Ray Spectrum of GNP-Gd(III)DO3A-SH-CTR 
Figures 10-12 demonstrate the quantification of gadolinium using Energy 
Dispersive X-ray Assay (EDAX), the spectrum of three samples GNP-Gd(III)DO3A-SH-
AS1411, GNP-Gd(III)DO3A-SH-CRO, and GNP-Gd(III)DO3A-SH-CTR. X-ray counts 
were plotted vs. energy (in keV). Energy peaks coincide with the various elements in each 
sample. 
Table 4: Atomic and Weight percentages of elements analyzed in Energy Dispersive X-







Element  Wt. %  At % 
 C K 21.34 38.95 
 O K 16 21.93 
 NaK 27.57 26.29 
 AuM 15.06 1.68 
 ClK 14.95 9.24 
 K K 2.88 1.61 
 GdL 2.21 0.31 
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 Table 5: Atomic and Weight percentages of elements analyzed in Energy Dispersive X-







Table 6: Atomic and Weight percentages of elements analyzed in Energy Dispersive X-






Tables 4-6 show the atomic and weight percentages of elements in each sample. 




3.3 MRI Phantom: 
To evaluate contrast enhancement by GNP–Gd(III)DO3A-SH-Oligonucleotide, the 
longitudinal T1 relaxation and T1-Weighted measurements were made at nanomolar GNP 
Element Wt.% At% 
  CK 27.13 52.39 
  OK 22.84 33.11 
 NaK 8.04 8.11 
 MgK 0.62 0.59 
 ClK 0.89 0.58 
  KK 0.67 0.4 
 GdL 4.02 0.59 
 AuL 35.78 4.21 
Element  Wt. %  At % 
 C K 7.85 40.77 
 SiK 15.6 34.64 
 AuM 71.99 22.79 
 GdL 4.55 1.8 
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concentrations (1200, 300, 75 nM) and compared with GNP-SH-Oligonucleotides as a 
control (figure 13) 
 
 
Figure 13: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide. 
 
The % Relaxivity enhancement was calculated as described in the method section. 
As demonstrated in Figure 10, as we increase the concentration of GNP–Gd(III)DO3A-SH-
Oligonucleotide there is increase in the percentage of relaxivity enhancement. 
 
3.4 In vitro imaging results: 
To evaluate the selective targeting induced contrast enhancement by GNP–
Gd(III)DO3A-SH-Oligonucleotide, the longitudinal T1 relaxation and T1-Weighted 
measurements were made at nanomolar GNP concentrations (1200, 300, 75 nM) and 
compared with corresponding clinically relevant Multihance concentrations (1700, 7000, 
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27900 nM) in breast cancer cells (MDA-MB-231) and non-malignant breast epithelial cells 
(MCF-10A). For control experiments with MultiHance, the concentrations (1700, 7000, 
27900 nM) were obtained by quantifying the Gd content per GNP using Energy Dispersive 
X-Ray (EDAX) analysis procedures (17, 18). The atomic ratios of Gd:Au were 
subsequently measured to quantify Gd content per GNP. MRI scans were applied to the 
treated cells after incubation for four time intervals (24, 48, 72, and 96). 
 
Table 7: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MDA-MB-231 & MCF-10A cell lines using T1-Weighted image 









Figure 14: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MCF-10A cell line using T1-Weighted image analysis algorithm after 
24 hours. 
 
Figure 15: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotides in MCF-10A cell line using T1-Weighted image analysis algorithm 




Figure 16: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MCF-10A cell line using T1-Weighted image analysis algorithm after 
72 hours. 
 
Figure 17: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 





Figure 18: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm 
after 24 hours. 
 
Figure 19: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm 




Figure 20: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm 
after 72 hours. 
 
Figure 21: T1-Weighted contrast enhancement comparison for GNP Gd(III)DO3A-SH 
Oligonucleotide in MDA-MB-231 cell line using T1-Weighted image analysis algorithm 
after 96 hours. 
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As demonstrated in table 7 and figures 14-21 the enhancement of MRI relaxivity 
using GNP Gd(III)DO3A-SH Oligonucleotide is higher for MDA-MB-231 images than 
MCF-10A images upon the selective accumulation in cancer cells. MRI images were 
analyzed using T1-Weighted image analysis algorithm (as described in the methods 
section), Samples of GNP–Gd(III)DO3A-SH-AS1411/CRO display significantly higher 
relaxivity values compared to GNP–Gd(III)DO3A-SH-CTR at 24 hours. While GNP–
Gd(III)DO3A-SH-AS1411 displays the highest enhancement of relaxivity values at 48, 72, 
96 hours upon selective targeting (and retention inside) of cancer cells upon binding with 
nucleolin protein which is highly expressed in the cytoplasm and cell surface (highest 
enhancement achieves at 72 hours). 
 
3.4  In Vivo Biodistribution Study: 
(a) Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Results:  
The biodistribution of gold nanoparticles in seven organs (brain, heart, lung, large 
intestine, kidney, spleen, and liver) had been investigated by ICP-MS. Seven organs were 
collected after the injection of the five treatment groups by 2 or 14 days. 




 To simplify the figures, CTR stands for GNP Gd (lll) DO3A-SH CTR, CRO 
stands for GNP Gd (lll) DO3A-SH CRO, and AS1411 stands for GNP Gd (lll) 
DO3A-SH AS1411. 
  
ICP-MS results show the biodistribution of gold nanoparticles in seven organs 
(brain, heart, lung, large intestine, kidney, spleen, and liver) of 50 rats after injection with 
GNP–Gd(III)DO3A-SH- oligonucleotides, saline, and MultiHance. Animals were 
sacrificed after 2 and 14 days of injections. The liver and spleen show the highest 
concentration of gold nanoparticles with respect to other organs. Moreover, the 
concentrations of the particles on day 14 are less than the concentrations in day 2 for both 
organs, suggesting ongoing clearance of nanoparticles from these organs.  
 
(b) Blood Chemistry Analysis: 
Blood samples were drawn from the rats after treatment with GNP Gd (lll) DO3A-
SH AS1411, GNP Gd (lll) DO3A-SH CRO, GNP Gd (lll) DO3A-SH CTR, MultiHance, 
and Saline for blood analysis at 2 time points (2 or 14 day). Five blood biomarkers (BUN, 





Figure 23: BUN post-treatment blood concentrations of 5 treatment groups. 
Figure 24: CREA post-treatment blood concentrations of 5 treatment groups 




Figure 26: ALKP post-treatment blood concentrations of 5 treatment groups. 
 
Figure 27: TBIL post-treatment blood concentrations of 5 treatment groups. 
 
 To simplify the figures, CTR stands for GNP Gd (lll) DO3A-SH CTR, CRO 
stands for GNP Gd (lll) DO3A-SH CRO, and AS1411 stands for GNP Gd (lll) 
DO3A-SH AS1411. 
  
As demonstrated in figures 23-27 the post-treatment blood levels of BUN (mg/dL), 
CREA (mg/dL), ALT (U/L), ALKP (U/L), and TBIL (mg/dL) were plotted for the five 




(c) Statistical Analysis: 
We performed two statistical tests on the blood chemistry results to analyze the data 
that were collected. The first test is based on using unpaired t-tests by assuming all the 
involved biomarkers in this experiment are independent. The second statistical test is based 
on using ANOVA test in order to make a group analysis in case the collected biomarkers 
are dependent/correlated.  
First, post-treatment blood biomarkers BUN, CREA, ALT, ALKP, and TBIL 
values were analyzed by using unpaired T test, Tables 8 and 9.  The blood biomarkers for 
each group (MultiHance, GNP Gd (lll) DO3A-SH CTR, GNP Gd (lll) DO3A-SH CRO, 
GNP Gd (lll) DO3A-SH As1411) were compared with blood biomarkers for a saline control 
group at days 2 and 14 respectively. As demonstrated in Table 8, the statistical results show 
that all of the variables do not have a significant difference between GNP Gd (lll) DOA3-
SH AS1411 and control group at day 2.  However, the unpaired t-test detects significant 
differences occur for BUN and CREA biomarkers for the following post-treatment agents: 
MultiHance, GNP Gd (lll) DOA3-CTR, and Gd (lll) DOA3-CRO as demonstrated by bold 
highlighted values in Table 8.  In a similar way, Table 9 shows the estimated P-values by 
day 14.  It is clear that there are no significant differences between biomarkers blood levels 
of the animals injected with test solution GNP Gd(III)-DO3A-SH-AS1411 and biomarkers 













Saline & GNP 
Gd (lll) DO3A-
SH CTR 
Saline & GNP 
Gd (lll) DO3A-
SH CRO 
Saline & GNP 
Gd (lll) DO3A-
SH AS1411 
BUN 0.0078 0.0085 0.0073 0.3322 
CREA 1.000 1.000 0.0278 1.000 
ALT 0.1605 0.1605 0.0795BUN, 
CREA 
0.2196 
ALKP 0.0565 0.0565 0.7108 0.0515 
TBIL 1.000 1.000 0.8836 0.6305 
 





Saline & GNP 
Gd (lll) DO3A-
SH CTR 




GNP Gd (lll) 
DO3A-SH 
AS1411 
BUN 0.4482 0.9152 0.9256 0.2155 
CREA 1.000 1.000 1.000 Perfect data 
ALT 0.4253 0.1713 0.6656 0.0844 
ALKP 0.8178 0.5414 0.3824 0.9619 
TBIL 1.000 0.1525 0.6317 1.000 
 
For more investigation, we performed an ANOVA test in case there are correlations 
between the measured biomarkers. In this statistical test, we used a factorial design with 
post- treatment interval (2 days or 14 days) and treatment agents, along with their 
interaction effect. The dependent variables were the log-transformed post-treatment 
biomarkers relative to control: in (BUNTest / BUNControl), etc. The linear model was fit 
to each biomarker independently. The ANOVA was performed to test whether there was 
any significant treatment agent-dependence on the change in biomarker levels. The results 
show that the BUN, ALT, ALKP, and TBIL data were not significantly different from our 
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null hypothesis that there is a significant treatment agent-dependence on the change in 
biomarker levels (χ2 = 15.2, 12.3, 12.5, 9.45 respectively, with 9 degrees of freedom [d.f.]; 
p = 0.08, 0.20, 0.19, and 0.051 respectively).  
Both statistical tests (unpaired t-tests and ANOVA) demonstrate that there are no 
significant difference in post-treatment blood levels of BUN, ALT, CREA, ALKP, and 
TBIL between GNP Gd (lll) DOA3-SH AS1411 and saline group, which means the 
proposed contrast agent (Gd (lll) DOA3-SH AS1411) does not affect liver and kidney 






























CHAPTER 4: CONCLUSIONS 
 
 
We have developed cancer-targeted gold nanoparticle-based MRI contrast agent 
consisting of: a 4 nm diameter gold nanoparticle, cancer targeting DNA aptamer (AS1411), 
and a gadolinium chelate contrast agent (Gd(III)-DO3A-SH). The particles were 
characterized using DLS, UV-vis, and TEM. Zeta potential for GNP Gd (lll) DOA3-SH 
AS1411 was -20.9 ± 1.1 which, displayed high stability. The selective targeting ability was 
evaluated by in-vitro study using MDA-MB-231 and MCF-10A cell lines. AS1411 is 
included in the coating to allow the nanoparticles to be selectively retained in cancer cells 
upon binding to nucleolin protein, which is expressed on the cell surface and in the 
cytoplasm of cancer cells. Since nucleolin is found solely in the nucleus of healthy cells, 
where it is unavailable for binding to our nanoparticles, AS1411-coated particles are not 
retained in healthy cells.  
Oligonucleotide anchoring to the nanoparticle surface, along with steric crowding 
within the corona monolayer, slows the rotational tumbling rate of the Gd3+ chelate and 
therefore reduces the T1 relaxation time, hence increasing the T1-Weighted image contrast 
of GNP–Gd(III)DO3A-SH-Oligonucleotide. The local voxel wise and global image 
analysis of T1- Weighted algorithm on GNP–Gd(III)DO3A-SH-Oligonucleotide construct 
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has shown exceptional contrast enhancement for MDA-MD-231 cells targeted by the 
cancer specific contrast agent GNP-Gd(III)DO3A-SH-AS1411 compared to its non-
targeted control counterparts GNP-Gd(III)-DO3A-SH-CRO/CTR. The nucleolin binding 
ability of AS1411 oligonucleotide has led to selective accumulation of gadolinium-based 
contrast agent (GBCA) in cancer cells (MDA-MB-231) accomplishing superior contrast 
enhancement over non-malignant breast epithelial cells (MCF-10A). Moreover, the T1-
Weighted image analysis algorithm features steric bulk-induced longitudinal changes by 
yielding significantly higher T1-Weighted image for GBCA with longer sequence 
oligonucleotides (AS1411/CRO) in comparison to their shorter sequence counterpart CTR, 
particularly in the breast cancer cells. All of these studies suggest that GNP-Gd(III)DO3A-
SH-AS1411 has the potential use of enabling discrimination between cancerous and 
healthy tissue using MRI. 
Our in-vivo toxicity and biodistribution study shows that the proposed contrast 
agent GNP (Gd(III)-DO3A-SH-AS1411 is not toxic for healthy rats. ICP-MS analysis 
demonstrates that the particles were cleared from all body organs Although there are 
elevated levels of GNP-Gd(III)DO3A-SH-AS1411 in the liver and spleen, the 
concentrations of the particles on day 14 are less than the concentrations in day 2 for both 
organs, suggesting ongoing clearance of nanoparticles from these organs.  
We selected five blood biomarkers to evaluate the toxicity of the contrast agent. 
BUN and CREA were used to evaluate kidney function and ALT, TBIL, and ALKP were 
used to evaluate liver function. Our statistical analysis results show that there is not any 
significant difference between biomarkers blood levels of the animals injected with test 
solution GNP Gd(III)-DO3A-SH-AS1411 and biomarkers blood levels of the animals 
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injected with saline solution.  
Our proposed cancer-targeted contrast agent (GNP (Gd(III)-DO3A-SH-AS1411) exhibits 
MRI contrast with higher relaxivity in cancer cells in comparison to normal cells by in vitro 
study ,and the particles were not toxic for healthy animals. The evidence thus far suggests 
that GNP-Gd(III)DO3A-SH-AS1411 is worth investigating further both in vitro and in vivo 
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